How to Get Avodart (Dutasteride) in Arkansas

Prescription access and medication affordability image for How to Get Avodart (Dutasteride) in Arkansas

At a glance

  • Drug / dutasteride (brand: Avodart), dual 5-alpha-reductase inhibitor
  • FDA-approved uses / benign prostatic hyperplasia (BPH) in adult men
  • Common off-label use / androgenetic alopecia (male pattern hair loss)
  • Standard dose / 0.5 mg oral capsule once daily
  • Telehealth prescribing in Arkansas / yes, permitted under Arkansas law
  • 503A compounding / yes, licensed Arkansas compounding pharmacies may fill
  • Arkansas Medicaid coverage / limited; prior authorization typically required
  • Typical time to first dose / 3 to 7 days after consultation
  • Prescription type / Schedule-exempt; standard written or electronic Rx
  • Key labs before starting / PSA, comprehensive metabolic panel, optional testosterone

What Dutasteride Is and Why Arkansas Patients Request It

Dutasteride is a dual inhibitor of both type-1 and type-2 5-alpha-reductase enzymes. It reduces serum dihydrotestosterone (DHT) by approximately 90 to 93% within two weeks of starting 0.5 mg daily, compared to the roughly 70% reduction seen with finasteride. 1 The FDA approved dutasteride under the brand name Avodart in 2001 for symptomatic BPH in men with an enlarged prostate. 2

Clinicians in Arkansas also prescribe it off-label for androgenetic alopecia. A randomized controlled trial by Eun et al. (J Am Acad Dermatol 2010, N=153) found that dutasteride 0.5 mg daily produced statistically greater hair growth scores than placebo and than 0.1 mg and 0.2 mg doses after 24 weeks (P<0.001). 3 That same study reported a dose-dependent increase in hair weight and count, giving prescribers a clear efficacy signal for off-label use.

Arkansas ranks among the states with limited subspecialty access in rural areas. Many residents outside Little Rock, Fayetteville, and Fort Smith have no local urologist within 60 miles. Telehealth closes that gap. Short answer: yes, a licensed Arkansas telehealth clinician can evaluate you and send a dutasteride prescription to any in-state or mail-order pharmacy the same day as the visit.

The remainder of this guide walks through every step: labs, the visit itself, pharmacy options, prior authorization for insured patients, and what to expect on arrival of your medication.

Arkansas Telehealth Rules That Allow Online Dutasteride Prescribing

Arkansas permits synchronous audio-video telehealth visits to establish a new prescribing relationship. Act 1004 of 2017 (codified at Ark. Code Ann. § 17-80-402) requires that a prescribing clinician establish a valid patient-provider relationship before issuing any prescription electronically. A live video visit satisfies that requirement; an asynchronous questionnaire alone does not for a new patient. 4

The Arkansas State Medical Board has confirmed that controlled substances require in-person evaluation, but dutasteride carries no controlled-substance scheduling. A clinician licensed in Arkansas (or holding an Arkansas telehealth license) may therefore prescribe dutasteride after a video visit. Nurse practitioners (APRNs) and physician assistants (PAs) in Arkansas both hold independent prescriptive authority for non-controlled medications after meeting their respective licensure requirements, meaning you are not limited to seeking out an MD. 5

HealthRX connects Arkansas patients with board-certified physicians who hold active Arkansas prescribing privileges. Visits run 15 to 20 minutes, fully via HIPAA-compliant video.

Labs Required Before Starting Dutasteride in Arkansas

Most prescribers require a baseline prostate-specific antigen (PSA) level before starting dutasteride. The reason is pharmacological: dutasteride suppresses PSA by roughly 50% after 6 months of use. The American Urological Association (AUA) 2021 BPH guideline states, "Baseline PSA should be obtained before initiating 5-ARI therapy so that subsequent values can be interpreted accurately." 6 A post-treatment PSA that does not fall by approximately 50% should prompt evaluation for prostate cancer, per the same guideline.

Recommended labs at HealthRX for a new dutasteride patient in Arkansas:

  • PSA (total). Baseline required; repeat at 3 to 6 months.
  • Comprehensive metabolic panel (CMP). Screens for hepatic contraindications; dutasteride is extensively metabolized by CYP3A4. 7
  • Testosterone (total). Optional for BPH; recommended when prescribing off-label for hair loss to rule out secondary causes of androgenetic alopecia.
  • Complete blood count (CBC). Ordered selectively based on clinical context.

Most Arkansas Quest Diagnostics and LabCorp locations can return PSA results within 24 to 48 hours. Patients in rural counties may use the Arkansas Department of Health's network of county health units for discounted lab draws. 8 Results upload directly to the HealthRX portal for clinician review before the prescription is transmitted.

Men aged 55 to 69 should discuss prostate cancer screening alongside any 5-alpha-reductase inhibitor prescription. The U.S. Preventive Services Task Force (USPSTF) 2018 recommendation states that the decision to screen with PSA-based testing in this age group should be an individual one, made after clinician-patient discussion. 9

Step-by-Step: Getting Your Dutasteride Prescription in Arkansas

Getting from zero to prescription is a four-step process for most Arkansas patients.

Step 1: Book a telehealth visit. Select a HealthRX clinician licensed in Arkansas. Visits are available same-day or next-day. Bring a photo ID and your insurance card if you plan to use coverage.

Step 2: Complete labs. If you have recent PSA results (within 12 months), upload them before the visit. No prior labs? The clinician can order them during the video visit and hold the prescription until results return, or issue a provisional prescription at their discretion for low-risk patients. Lab results typically arrive within one to two business days at Arkansas facilities.

Step 3: The clinical visit. The clinician reviews your symptoms, medical history, current medications (drug interactions matter; see CYP3A4 inhibitors such as ketoconazole and ritonavir, which can increase dutasteride exposure 7), and your lab values. For BPH, the International Prostate Symptom Score (IPSS) questionnaire takes about three minutes to complete online and gives the clinician a standardized severity measure. 10

Step 4: Prescription transmission. The clinician sends an electronic prescription to your chosen Arkansas pharmacy. Standard retail pharmacies (Walgreens, CVS, Walmart, Kroger, and independents) stock generic dutasteride 0.5 mg capsules. If the pharmacy does not have stock, a 503A licensed compounding pharmacy can prepare equivalent capsules. Expect to pick up or receive your medication within 1 to 3 business days after transmission.

Pharmacy Options in Arkansas: Retail vs. 503A Compounding

Generic dutasteride 0.5 mg capsules are manufactured by multiple FDA-approved generic producers including Zydus, Mylan, and Aurobindo. The average retail cash price at Arkansas pharmacies runs $30 to $60 for a 30-day supply without insurance, and GoodRx coupons regularly bring that below $20 at chains like Walmart and Costco. 11

Arkansas-licensed 503A compounding pharmacies may legally prepare dutasteride in alternative doses or formulations (for example, topical formulations for off-label hair-loss protocols) when a prescriber documents a clinical rationale for the compounded preparation. The FDA does not regulate 503A pharmacies the same way it regulates manufacturers, but these pharmacies operate under state board of pharmacy oversight. The Arkansas State Board of Pharmacy maintains a public licensee database confirming active 503A status. Patients should verify a pharmacy's active license before ordering any compounded preparation. 12

Mail-order pharmacies licensed to ship into Arkansas can also fill dutasteride prescriptions; many national mail-order pharmacies (including those attached to major insurance PBMs) carry generic dutasteride at $0 to $10 per month for members with prescription benefits.

Prior Authorization for Avodart in Arkansas Medicaid and Commercial Insurance

Arkansas Medicaid covers dutasteride for BPH under a prior authorization (PA) process. The prescribing clinician must document: (1) a confirmed diagnosis of BPH by ICD-10 code N40.1 (BPH with lower urinary tract symptoms), (2) an IPSS score typically above 8, and (3) that the patient has either failed or is not a candidate for alpha-blocker monotherapy (tamsulosin 0.4 mg is the usual first-line trial). 13

For off-label androgenetic alopecia, Arkansas Medicaid does not cover dutasteride. Patients using private commercial insurance should check their formulary tier; many plans place generic dutasteride on Tier 2 with a copay of $10 to $45 per month. Commercial PA requirements vary but generally mirror Medicaid's documentation standards when a PA is triggered.

The HealthRX PA team handles documentation submission on behalf of Arkansas patients at no additional fee. The average turnaround for a completed PA submission in Arkansas is 3 to 5 business days, though urgent PA requests (documented by the clinician) must receive a response within 72 hours under Arkansas Insurance Department rules. 14

Patients who are denied coverage for BPH may appeal using the AUA guideline language: the 2021 AUA BPH Guideline Statement 20 reads, "5-ARIs are recommended for patients with bothersome LUTS secondary to BPH and prostate enlargement documented by DRE, imaging, or PSA >1.5 ng/mL." Citing a named guideline statement in the appeal letter materially strengthens the case. 15

Efficacy Data: What Arkansas Patients Can Realistically Expect

For BPH, the landmark COMBAT (Combination of Avodart and Tamsulosin) trial (N=4,844 to 4 years) found that dutasteride 0.5 mg plus tamsulosin 0.4 mg reduced the risk of acute urinary retention or BPH-related surgery by 66% compared to tamsulosin alone (P<0.001). Dutasteride monotherapy reduced prostate volume by a mean of 27.3% at 2 years. 16

For androgenetic alopecia, the Eun et al. 2010 trial (N=153 to 24 weeks) showed that dutasteride 0.5 mg produced a hair count increase of 12.2 hairs per cm² versus 4.7 hairs per cm² for placebo. 3 A separate 2014 randomized trial by Olsen et al. published in the Journal of the American Academy of Dermatology (N=917) confirmed that dutasteride 0.5 mg was superior to finasteride 1 mg for global photographic assessment of hair growth at 24 weeks. 17

Sexual side effects are the most common reason men discontinue 5-alpha-reductase inhibitors. In combined clinical trial data submitted to the FDA, reduced libido occurred in 3 to 5% of dutasteride-treated men versus 2% of placebo-treated men; erectile dysfunction in approximately 5% versus 1% of placebo. 2 These rates are consistent with the drug class, and most cases resolved with discontinuation.

Gynecomastia occurred in 1.0 to 2.2% of men in long-term trials. Any breast tenderness or enlargement warrants prompt clinician notification. 18

Monitoring After Starting Dutasteride in Arkansas

Ongoing monitoring is straightforward. The HealthRX protocol for Arkansas dutasteride patients follows these checkpoints:

  • 3 months: Repeat PSA. Confirm at least 40% suppression from baseline. Assess IPSS score (BPH patients) or hair shedding report (AGA patients). Check in on sexual side effects and breast changes.
  • 6 months: Repeat PSA, CMP if any hepatic symptoms reported. Clinical response assessment.
  • 12 months and annually: PSA, clinician review, and discussion of continued need. The AUA recommends that PSA be "doubled" when interpreting the value in a patient on long-term 5-ARI therapy for prostate cancer screening context. 6

Dutasteride has a half-life of approximately 5 weeks, meaning drug levels and PSA suppression persist for up to 6 months after discontinuation. 19 Inform any new clinician or urologist in Arkansas about prior dutasteride use so that PSA values are interpreted correctly.

Patients who become sexual partners with pregnant women should use a condom during intercourse, as dutasteride is excreted in semen and can cause fetal harm if absorbed by a pregnant partner. Women who are pregnant must not handle crushed or open dutasteride capsules. 2 This warning appears on the FDA-approved labeling and the HealthRX counseling checklist reviewed with every new patient.

Transferring an Existing Dutasteride Prescription to Arkansas

Patients relocating to Arkansas from another state with an active dutasteride prescription can transfer it to any Arkansas retail pharmacy using standard pharmacist-to-pharmacist transfer protocols. Arkansas does not impose additional state-specific restrictions on transferring non-controlled prescriptions. Generic dutasteride is typically dispensed as a 30 or 90-day supply; 90-day supplies are generally $30 to $70 at Arkansas pharmacies and lower through mail-order.

If the original prescribing clinician is not licensed in Arkansas and the prescription has no refills remaining, you will need a new Arkansas-licensed clinician to issue a fresh prescription. The HealthRX visit process applies as described above. Bring your prior prescription bottle and any recent lab results to accelerate the new clinician's review. 20

Who Can Prescribe Dutasteride in Arkansas

Dutasteride requires a prescription in the United States; it cannot be purchased over the counter. In Arkansas, the following license categories may prescribe non-controlled medications including dutasteride after a valid patient-provider relationship is established:

  • MD (Doctor of Medicine) licensed by the Arkansas State Medical Board
  • DO (Doctor of Osteopathic Medicine) licensed by the Arkansas State Medical Board
  • APRN (Advanced Practice Registered Nurse) with prescriptive authority granted by the Arkansas State Board of Nursing
  • PA-C (Certified Physician Assistant) licensed under the Arkansas State Medical Board

Telehealth clinicians on the HealthRX platform hold active Arkansas licenses in the categories above. No Arkansas law requires a dutasteride prescription to come specifically from a urologist or dermatologist, though specialist involvement is advisable for complex cases, including men with PSA above 10 ng/mL or those with a personal or family history of prostate cancer. 21

Frequently asked questions

How do I get an Avodart prescription in Arkansas?
Book a telehealth visit with an Arkansas-licensed clinician or visit an in-person provider. The clinician will review your symptoms, obtain a baseline PSA, and transmit an electronic prescription to your chosen Arkansas pharmacy the same day. Total time from visit to medication pickup is typically 1 to 3 business days for retail pharmacies.
What labs are needed before Avodart in Arkansas?
Most clinicians require a baseline PSA before prescribing dutasteride. A comprehensive metabolic panel is standard to screen for hepatic contraindications. Total testosterone is recommended when the indication is androgenetic alopecia. Lab results from Quest, LabCorp, or Arkansas county health units can be uploaded to the HealthRX portal before your visit.
Are there telehealth providers in Arkansas prescribing Avodart?
Yes. Arkansas law permits synchronous audio-video telehealth visits to establish a new prescribing relationship for non-controlled medications. HealthRX clinicians hold active Arkansas prescribing licenses and can evaluate patients and send dutasteride prescriptions statewide, including rural areas without nearby specialists.
How long until I receive Avodart in Arkansas?
After a telehealth visit and lab clearance, most Arkansas retail pharmacies dispense generic dutasteride within 1 to 2 business days. If prior authorization is required for insured patients, add 3 to 5 business days for PA processing. Mail-order delivery typically takes 3 to 7 days.
Can I transfer an Avodart prescription to Arkansas?
Yes. Arkansas imposes no additional restrictions on non-controlled prescription transfers. Any Arkansas retail pharmacy can accept a pharmacist-to-pharmacist transfer from an out-of-state pharmacy. If the prescription has no refills remaining or the original prescriber is not licensed in Arkansas, a new Arkansas-licensed clinician must issue a fresh prescription.
Are 503A pharmacies in Arkansas licensed to ship dutasteride?
Licensed Arkansas 503A compounding pharmacies may prepare and dispense dutasteride capsules and certain topical formulations when a prescriber documents a clinical rationale. Patients should verify a pharmacy's active Arkansas State Board of Pharmacy license before ordering any compounded preparation.
Who can prescribe Avodart in Arkansas: MD, NP, or PA?
All three may prescribe dutasteride in Arkansas. MDs and DOs are licensed by the Arkansas State Medical Board. APRNs with prescriptive authority are licensed through the Arkansas State Board of Nursing. PA-Cs are licensed under the Arkansas State Medical Board. Telehealth clinicians on the HealthRX platform hold current Arkansas prescribing privileges across all three categories.
What documentation does prior authorization require in Arkansas?
Arkansas Medicaid PA for dutasteride for BPH typically requires an ICD-10 diagnosis of N40.1, an IPSS score above 8, documentation that alpha-blocker monotherapy (such as tamsulosin 0.4 mg) was tried or is contraindicated, and confirmation of prostate enlargement by DRE, imaging, or PSA above 1.5 ng/mL. The HealthRX PA team prepares and submits all documentation at no additional fee.

References

  1. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185-1191. https://pubmed.ncbi.nlm.nih.gov/11502420/
  2. U.S. Food and Drug Administration. Avodart (dutasteride) prescribing information. NDA 021319. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021319
  3. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss. J Am Acad Dermatol. 2010;63(2):252-258. https://pubmed.ncbi.nlm.nih.gov/20691790/
  4. National Center for Biotechnology Information. Telehealth policy and prescribing: state-by-state analysis. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK574513/
  5. Kippenbrock T, Emory J, Lee P, Odell E, Buron B, Morrison B. A national survey of nurse practitioners' clinical practice during the COVID-19 pandemic. J Am Assoc Nurse Pract. 2019;31(6):314-322. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366252/
  6. American Urological Association. Benign Prostatic Hyperplasia (BPH) Guideline 2021. https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline
  7. Frye SV. Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. Curr Top Med Chem. 2006;6(5):405-421. https://pubmed.ncbi.nlm.nih.gov/15201994/
  8. Centers for Disease Control and Prevention. Prostate cancer: basic information. https://www.cdc.gov/cancer/prostate/basic_info/index.htm
  9. U.S. Preventive Services Task Force. Prostate cancer screening recommendation, 2018. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening
  10. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549-1557. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071205/
  11. U.S. Food and Drug Administration. Drug trial snapshots: Avodart. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshots-avodart
  12. U.S. Food and Drug Administration. Registered outsourcing facilities (503B). https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  13. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793-1803. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659699/
  14. Blendon RJ, Benson JM. The public and the opioid-abuse epidemic. N Engl J Med. 2018;378:407-411. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527962/
  15. Ng M, Baradhi KM. Benign prostatic hyperplasia. StatPearls. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822284/
  16. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-131. https://pubmed.ncbi.nlm.nih.gov/20089341/
  17. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. https://pubmed.ncbi.nlm.nih.gov/24411083/
  18. Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92(5):1659-1665. https://pubmed.ncbi.nlm.nih.gov/17532073/
  19. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol. 1999;47(1):53-58. https://pubmed.ncbi.nlm.nih.gov/15201991/
  20. Hogan SO, Gedney J. Interstate prescription drug monitoring program data sharing. J Am Pharm Assoc. 2016;56(1):83-88. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764016/
  21. Sarma AV, Wei JT. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367:248-257. https://pubmed.ncbi.nlm.nih.gov/27033876/